Continuing Education Activity

Atherosclerosis is a leading cause of morbidity and mortality globally, and many interventions are performed to treat it. However, despite the potential benefits of these procedures, they may fail due to restenosis caused by neointimal hyperplasia (NIH). Neointimal hyperplasia refers to post-intervention, pathological, vascular remodeling due to the proliferation and migration of vascular smooth muscle cells in the tunica intima layer, resulting in vascular wall thickening and the gradual loss of luminal patency which may lead to the return of vascular insufficiency symptoms. This activity describes the pathophysiology of neointimal hyperplasia and highlights the role of the interprofessional team in managing these patients.

Objectives:

• Identify the etiology of neointimal hyperplasia.
• Describe the presenting features of neointimal hyperplasia.
• Outline the treatment options available for neointimal hyperplasia.
• Explain the importance of optimizing coordination amongst the interprofessional team to enhance care for patients affected by neointimal hyperplasia.

Introduction

Atherosclerosis is a leading cause of morbidity and mortality globally. Currently, many procedures are performed by interventionists and vascular surgeons to treat atherosclerosis, such as balloon angioplasty with or without stenting, endarterectomy, or surgical bypass grafting. However, despite the benefits, these interventions fail from restenosis due to neointimal hyperplasia (NIH). In a normal vasculature, smooth muscle cells (SMC) are found in the tunica media, and they are quiescent with minimal turnover and contractile phenotype. Neointimal hyperplasia refers to post-intervention, pathological, vascular remodeling due to the proliferation and migration of vascular smooth muscle cells into the tunica intima layer, resulting in vascular wall thickening and the gradual loss of luminal patency which may lead to the return of vascular insufficiency symptoms. [1][2] SMC in neointimal hyperplasia lose contractile phenotype, and they differentiate into secretory phenotype predominantly. These modified SMC secrete the growth factors, growth factor receptors, extracellular matrix, proteinases, and inflammatory mediators responsible for neointimal hyperplasia. Many vascular interventions put vessels at risk of injury, leading to restenosis due to activation of the inflammatory cascade and cellular recruitment. It is most evident in "in-stent restenosis" after the plain old balloon angioplasty (POBA) without stenting and percutaneous coronary intervention with bare-metal stenting. Metallic stents were necessary to counteract acute vascular recoil after POBA, but after serving this purpose, long-term in situ metallic platform injure the vascular wall and sets in chronic inflammation and hyperplasia of the vascular intimal layer. Other vascular manipulation also may result in vessel injury, leading to neointimal hyperplasia.

There are two types of neointimal hyperplasia.

1. Arterial neointimal hyperplasia secondary to arterial manipulation in endarterectomy or angioplasty. [3]
2. Venous graft associated neointimal hyperplasia secondary to coronary artery bypass grafting or arteriovenous grafting/ fistula formation. [4]

Etiology

Vascular wall injury may be due to manipulation by any of the following procedures:

• Use of angioplasty catheter and balloon inflation during the angioplasty.
• Use of an embolectomy catheter.
• Vascular endarterectomy. 
• Small target veins used in arteriovenous fistula creation. 
• Coronary vein grafting or coronary artery bypass grafting (CABG).

Epidemiology

• The patency rate of the venous graft used during CABG is 80% at one year and 60% at five years. A saphenous venous graft (SVG) is more prone to intimal hyperplasia and stenosis than an internal mammary artery graft. However, late-onset occlusion of SVG after five years of grafting is almost always due to neo-atherosclerosis. 
• Arteriovenous (AV) fistula or graft is used as a vascular access site for hemodialysis in patients with end-stage renal disease (ESRD) on dialysis. Arteriovenous (AV) fistula or graft failure rate varies between 30% to 60% at one year. Recent studies have indicated that neointimal hyperplasia is the most common underlying pathology in 30% to 60% of AV grafts or fistula failures followed by vascular thrombosis.

Pathophysiology

The events leading to neointimal hyperplasia can be broadly classified into the following:

• Endothelial dysfunction and activation
• Platelet activation and thrombus formation
• Leucocyte recruitment
• Smooth muscle cell migration and proliferation

The primary pathology is the proliferation and migration of smooth muscle cells (SMCs) in the tunica intima layer. The triggering step is endothelial damage or dysfunction (ED) due to vascular injury, which can occur secondary to a vascular wall stretching during balloon angioplasty, vascular manipulation during carotid endarterectomy, or venous graft implantation during arteriovenous fistula formation or coronary bypass grafting. [1] ED leads to endothelial activation and decreases the production of nitrous oxide (NO) due to the dysregulation of endothelial nitric oxide synthase (ENOS). [5][6] When platelets come in contact with activated endothelial cells, it forms a platelet-rich thrombus. An inflammatory cascade begins at the vascular injury site, and leukocytes demarginate from the bloodstream and reach sub-endothelial thrombus. Oxidative stress promotes the expression of endothelial adhesion molecules, such as vascular cell adhesion molecules, that help recruitment and migration of monocytes into the subendothelial area. [7][2]

Matrix metalloproteinases are key enzymes that cause the breakdown of extracellular matrix proteins, such as collagen and elastin, and facilitate the migration of vascular SMCs across internal elastic lamina in neointimal hyperplasia formation. [8]It is also noted in arteriovenous grafts studies that SMCs can alternately originate from fibroblasts from vascular adventitia or bone marrow progenitor cells. [2][9] Once SMCs migrate at the vascular injury site intimal layer, they go through a phenotypic transition from predominantly contractile to secretory type SMCs.

Histopathology

In both arterial and venous neointimal hyperplasia, there is SMC and fibroblast accumulation in the tunica intima layer with extracellular matrix (ECM) or collagen deposition. On immunohistochemistry studies, vascular samples with neointimal hyperplasia show multi-layered SMCs, which stain positive for alpha-smooth muscle actin, endothelial cells staining positive for anti-von Willebrand factor antibodies, fibroblasts which secrete ECM, lymphocytes, and macrophages. The excessive cellular deposition results in the expansion of the intimal layer and loss of the luminal area. [10] Tunica media layer in arterial neointimal hyperplasia tends to remain thin despite the increased thickness of the intimal layer. This is in contrast to vein graft adaptation, where there is also a concurrent expansion of the tunica media layer. [4][11][12][13]

History and Physical

Neointimal hyperplasia may be associated with recurrence of symptoms such as.

• Anginal symptoms or acute coronary syndrome for coronary artery venous graft or stenting with critical flow-limiting graft stenosis.
• AV graft or fistula failure leading to vascular access complication and delayed hemodialysis in ESRD patients on hemodialysis.
• Post carotid endarterectomy (CEA) restenosis due to neointimal hyperplasia can present with a transient ischemic attack (TIA) or stroke symptoms.

Evaluation

Workup should include the following:

• Angiography
• Intravascular ultrasonography
• Intravascular optical coherence tomography and correlation with histological findings of neointimal hyperplasia
• Flow Doppler catheters to document flow limitation 
• Graft surveillance to detect and repair neointimal hyperplasia early
• Carotid Doppler ultrasonography

Treatment / Management

Pharmacotherapy targeted at different steps of the pathogenesis of neointimal hyperplasia can be used to prevent and treat this condition. Graft surveillance in high-risk patients with serial Doppler ultrasound within the first two years after the vascular intervention can detect and repair neointimal hyperplasia. [10]

• Platelet activation and thrombus formation: Aspirin, P2Y12 (clopidogrel), glycoprotein IIb/IIIa inhibitors (abciximab), heparin, or hirudin targets this step to prevent neointimal hyperplasia.
• Leucocyte recruitment: Probucol is an antioxidant that prevents neointimal hyperplasia by blocking leukocytes recruitment into the sub-endothelial area of an injured vascular wall.
• SMC migration and proliferation:

1. NO deficiency secondary to ED has been linked with the neointimal hyperplasia development. Local NO-based perivascular powder therapy and poly (diol-co-citrate) elastomeric vascular wraps are superior to systemic NO therapies, which have adverse outcomes. [14]
2. Drug-eluting stents (DES) containing paclitaxel or everolimus also blocks SMC migration and proliferation. DES recently has been used in post-carotid endarterectomy restenosis cases in addition to their well-known use in coronary angioplasty with stenting. [15][16]
3. Gene therapy targeting SMC migration, proliferation, and NO production have also been studied.
4. Beta vascular brachytherapy has been proven to reduce neointimal hyperplasia burden after a few months. [17][18]

Differential Diagnosis

The following conditions can present similarly and need to be considered along with neointimal hyperplasia:

• Neoatherosclerosis
• Late stent thrombosis

Prognosis

Determination of neointimal characteristics is useful in predicting long-term clinical outcomes. Data suggests that heterogeneous lesions are linked to poor long-term clinical prognoses.

Complications

Depending on the organ system involved, vascular insufficiency can lead to the following:

• The recurrence of angina or acute myocardial infarction.
• AV fistula or graft failure, which leads to a delay in hemodialysis due to loss of vascular access.
• Transient ischemic attacks or cerebrovascular accident due to post carotid endarterectomy restenosis or thrombosis.

Consultations

Multidisciplinary team consultation may be required with the following:

• Interventional cardiologists
• Cardiothoracic surgeons
• Interventional radiologists
• Vascular surgeons
• Oncologists
• Rehabilitation team members

Deterrence and Patient Education

To improve patient outcomes, the key is to prevent this disease process in the first place. This means patient education about the benefits of exercise, smoking discontinuation, eating a healthy diet, and not leading a sedentary lifestyle.

Enhancing Healthcare Team Outcomes

Atherosclerosis can affect almost any vessel and lead to obstruction of blood flow. To improve patient outcomes, the key is to prevent this disease process in the first place. This means patient education about the benefits of exercise, smoking discontinuation, eating a healthy diet, and not leading a sedentary lifestyle.

Healthcare workers, including the pharmacist and nurse, have to monitor the patient's body weight, lipid levels, blood sugar, and blood pressure regularly. When conservative methods fail to control these parameters, drug therapy may be in order.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Bonatti J, Oberhuber A, Schachner T, Zou Y, Hammerer-Lercher A, Mittermair R, Laufer G. Neointimal Hyperplasia in Coronary Vein Grafts: Pathophysiology and Prevention of a Significant Clinical Problem. Heart Surg Forum. 2004 Jan 01;7(1):72-87. [PubMed: 14980855]

2.

Shoji M, Koba S, Kobayashi Y. Roles of bone-marrow-derived cells and inflammatory cytokines in neointimal hyperplasia after vascular injury. Biomed Res Int. 2014;2014:945127. [PMC free article: PMC3914557] [PubMed: 24551856]

3.

Subbotin VM. Analysis of arterial intimal hyperplasia: review and hypothesis. Theor Biol Med Model. 2007 Oct 31;4:41. [PMC free article: PMC2169223] [PubMed: 17974015]

4.

Shenoy S, Allon M, Beathard G, Brouwer-Maier D, Dember LM, Glickman M, Lee C, Litchfield T, Lok C, Huber T, Roy-Chaudhury P, Work J, West M, Wasse H. Clinical Trial End Points for Hemodialysis Vascular Access: Background, Rationale, and Definitions. Clin J Am Soc Nephrol. 2018 Mar 07;13(3):490-494. [PMC free article: PMC5967685] [PubMed: 29487092]

5.

Lavin B, Gómez M, Pello OM, Castejon B, Piedras MJ, Saura M, Zaragoza C. Nitric oxide prevents aortic neointimal hyperplasia by controlling macrophage polarization. Arterioscler Thromb Vasc Biol. 2014 Aug;34(8):1739-46. [PubMed: 24925976]

6.

Bahnson ES, Koo N, Cantu-Medellin N, Tsui AY, Havelka GE, Vercammen JM, Jiang Q, Kelley EE, Kibbe MR. Nitric oxide inhibits neointimal hyperplasia following vascular injury via differential, cell-specific modulation of SOD-1 in the arterial wall. Nitric Oxide. 2015 Jan 30;44:8-17. [PMC free article: PMC4304904] [PubMed: 25460325]

7.

Cai Y, Nagel DJ, Zhou Q, Cygnar KD, Zhao H, Li F, Pi X, Knight PA, Yan C. Role of cAMP-phosphodiesterase 1C signaling in regulating growth factor receptor stability, vascular smooth muscle cell growth, migration, and neointimal hyperplasia. Circ Res. 2015 Mar 27;116(7):1120-32. [PMC free article: PMC4702253] [PubMed: 25608528]

8.

Rotmans JI, Velema E, Verhagen HJ, Blankensteijn JD, de Kleijn DP, Stroes ES, Pasterkamp G. Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model. J Vasc Surg. 2004 Feb;39(2):432-9. [PubMed: 14743149]

9.

Diao Y, Guthrie S, Xia SL, Ouyang X, Zhang L, Xue J, Lee P, Grant M, Scott E, Segal MS. Long-term engraftment of bone marrow-derived cells in the intimal hyperplasia lesion of autologous vein grafts. Am J Pathol. 2008 Mar;172(3):839-48. [PMC free article: PMC2258265] [PubMed: 18276778]

10.

Collins MJ, Li X, Lv W, Yang C, Protack CD, Muto A, Jadlowiec CC, Shu C, Dardik A. Therapeutic strategies to combat neointimal hyperplasia in vascular grafts. Expert Rev Cardiovasc Ther. 2012 May;10(5):635-47. [PMC free article: PMC3401520] [PubMed: 22651839]

11.

Lee T, Roy-Chaudhury P. Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis. Adv Chronic Kidney Dis. 2009 Sep;16(5):329-38. [PMC free article: PMC2764321] [PubMed: 19695501]

12.

Li L, Terry CM, Blumenthal DK, Kuji T, Masaki T, Kwan BC, Zhuplatov I, Leypoldt JK, Cheung AK. Cellular and morphological changes during neointimal hyperplasia development in a porcine arteriovenous graft model. Nephrol Dial Transplant. 2007 Nov;22(11):3139-46. [PubMed: 17602194]

13.

Mitra AK, Gangahar DM, Agrawal DK. Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia. Immunol Cell Biol. 2006 Apr;84(2):115-24. [PubMed: 16519729]

14.

Serrano MC, Vavra AK, Jen M, Hogg ME, Murar J, Martinez J, Keefer LK, Ameer GA, Kibbe MR. Poly(diol-co-citrate)s as novel elastomeric perivascular wraps for the reduction of neointimal hyperplasia. Macromol Biosci. 2011 May 12;11(5):700-9. [PMC free article: PMC4068126] [PubMed: 21341372]

15.

Del Giudice C, Pellerin O, Gandini R, Sapoval M. Commentary: drug-coated balloon angioplasty to improve carotid stenting outcomes after postendarterectomy restenosis: fad or an answer to the problem of recurrent restenosis? J Endovasc Ther. 2015 Apr;22(2):217-9. [PubMed: 25809365]

16.

Zhou W, Lin PH, Bush RL, Peden EK, Guerrero MA, Kougias P, Lumsden AB. Management of in-sent restenosis after carotid artery stenting in high-risk patients. J Vasc Surg. 2006 Feb;43(2):305-12. [PubMed: 16476606]

17.

Werner M, Scheinert D, Henn M, Scheinert S, Bräunlich S, Bausback Y, Friedenberger J, Schuster J, Hertting K, Piorkowski M, Rosner C, Schmidt A, Ulrich M, Gutberlet M. Endovascular brachytherapy using liquid Beta-emitting rhenium-188 for the treatment of long-segment femoropopliteal in-stent stenosis. J Endovasc Ther. 2012 Aug;19(4):467-75. [PubMed: 22891824]

18.

Dheer A, Dutta SK. Intracoronary Radiation. Med J Armed Forces India. 2003 Apr;59(2):136-9. [PMC free article: PMC4923782] [PubMed: 27407488]

Disclosure: Muhammad Zain declares no relevant financial relationships with ineligible companies.

Disclosure: Radia Jamil declares no relevant financial relationships with ineligible companies.

Disclosure: Waqas Siddiqui declares no relevant financial relationships with ineligible companies.